FDA NEWS RELEASE
For Immediate Release: Feb. 11, 2011
Media Inquiries: Erica Jefferson, 301-796-4988, firstname.lastname@example.org
Consumer Inquiries: 888-INFO-FDA
FDA clears test to help patients with kidney transplants
Test monitors level of a drug that helps prevent kidney rejection
The U.S. Food and Drug Administration today announced that it has cleared a test to help manage potential organ rejection in kidney transplant patients. The test, called QMS Everolimus Immunoassay, monitors the blood level of everolimus, a drug that helps prevent rejection in kidney transplants.
Everolimus, marketed under the trade name Zortress, was approved by FDA in April 2010 for use in adult kidney transplant patients who are at low-to-moderate immunologic risk.
Transplant patients are routinely given drugs that suppress the immune system (immunosuppressants) such as a regimen containing everolimus, cyclosporine, basiliximab, and corticosteroids. These drugs help prevent organ rejection, which occurs when the body’s immune system attacks and destroys a transplanted organ.
Some immunosuppressants are associated with toxic side effects that can injure transplanted kidneys. Balancing the levels of immunosuppressants is critical since transplant patients must take these drugs for the rest of their lives.
“QMS Everolimus is the first FDA-cleared test physicians can use to maintain appropriate levels of the immunosuppressant everolimus,” said Jeffrey Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health.
QMS Everolimus is one of a number of FDA-cleared or -approved tests physicians can use to monitor and manage immunosuppressant levels, including tests for cyclosporine, tacrolimus, and sirolimus. These tests, along with careful monitoring of clinical signs and symptoms of organ rejection, tissue biopsies, and other lab tests, may increase the chance of having a successful transplant and possibly extend the survival of a transplanted kidney.
In addition to other evaluations, Thermofisher, the manufacturer of QMS Everolimus, demonstrated the performance of the test by comparing results from the new test to the results from everolimus reference tests used in the clinical trial of everolimus. When the clinical trial blood samples were tested with QMS Everolimus, the results, on average, were similar to those of the clinical trial reference test.
More than 87,000 patients are awaiting a kidney transplant in the United States, according to the Health Resources and Services Administration’s Organ Procurement and Transplantation Network.
QMS Everolimus is manufactured by Waltham, Mass.-based Thermofisher. Zortress is marketed by East Hanover, N.J.-based Novartis. 【drug-news】FDA顾问委员会建议批准Celebrex(塞来西布)用于儿a patient registry to track for up to three decades health indicators like blood ... FDA一顾问小组周三以15票对1票的投票结果建议批准辉瑞公司的止疼药Celebrex用于儿...www.med66.com/...6f05e4232.htm-2006-12-04-快照-【drug-news】FDA顾问委员会建议批准Celebrex(塞来西布)用于儿" 【drug-news】FDA:长期使用高剂量质子泵抑制剂存在骨折风险 ...发表时间：2010-12-25回帖数：4fda: possible fracture risk with high dose, long-term use of proton pump inhibitors ... treat the patient's condition.” fda's warning and decision to revise the labeling of ...www.ruanjian520.com/thread-... - 2010-12-25-快照-【drug-news】FDA:长期使用高剂量质子泵抑制剂存在骨折风险 ..." 【drug-news】FDA Finds Consumers Continue to Buy ...【drug-news】FDA Finds Consumers Continue to Buy Potentially Risky Drugs Over... and/or periodic patient monitoring; 可能有危险而需要筛选和/或定期监测患者; cause ...medicine.cadjy.com/...-9438115-2011-01-04-快照-【drug-news】FDA Finds Consumers Continue to Buy ..."[标签:content2]
作者:admin@医学,生命科学 2011-02-13 01:38